This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

IBM Launches University Competition To Combat Growth Of Non-Communicable Diseases

ARMONK, N.Y., Oct. 7, 2011 /PRNewswire/ -- IBM (NYSE: IBM) and Novartis (NYSE: NVS) today announced the NCD Challenge, a competition among a number of the world's leading universities designed to tap the inventiveness of students to find new ways to address the rise of non-communicable diseases in both developing and developed countries.

(Logo: http://photos.prnewswire.com/prnh/20090416/IBMLOGO)

Illnesses such as heart disease, stroke, cancer, asthma and diabetes are a global growing health concern with a far-reaching impact on the world's healthcare systems. The NCD Challenge is engaging teams of university students and faculty to design creative and entrepreneurial solutions to this growing problem.

According to the World Health Organization, nearly two-thirds of all deaths occur due to non-communicable diseases, of which almost 80 percent are in developing countries. Over the coming decade, some 388 million people worldwide will die of one or more chronic illnesses. However, with concerted action, research and new innovations, at least 36 million premature deaths could be averted by 2015.

Competing teams in the NCD Challenge will have a broad range of flexibility to develop new solutions that can scale to support both large and small populations in developing and developed countries. Each will compete to create new ways to promote disease awareness, to use technology to combat NCDs, and promote more efficient ways to provide care. The teams are supported by IBM and Novartis with mentors and subject matter coaching to provide industry expertise that will complement their knowledge and research.

IBM and Novartis created the competition to bring together industry and academia and act as a catalyst for new thinking in this area.  "Encouraging innovation and engaging university teams to address the unmet needs of millions of patients affected by chronic illness could have a far-reaching impact on our healthcare system," said Katherine Holland, general manager, IBM Life Sciences. "IBM and Novartis are jointly sponsoring this competition to encourage the creation of new solutions that will make a difference to one of the world's major health epidemics."  

Universities participating in the competition include: University of California, Berkeley Haas School of Business; Duke University School of Medicine; Schulich School of Business; University of Melbourne;  London Business School; Said Business School, University of Oxford; University of Fribourg, in collaboration with Inselspital Bern;  Karolinska Institutet; Copenhagen Business School; and Jordan University.

The competition will run through December 9, 2011. Winners will be announced in January.

The NCD Challenge is a key part of IBM's Celebration of Service, a program designed for IBMers around the world to volunteer and help with civic challenges and societal needs. This year marks IBM's centennial and healthcare continues to be one of its most important areas of industry focus. The company spends more than $6B a year on R&D and IBM is one of the few technology companies with large teams of physicians and other clinicians on staff to ensure healthcare's most pressing needs are met.

To learn more about the NCD Challenge please visit: www.ncdchallenge.com

About IBM

For more information about IBM, visit: http://www.ibm.com/smarterhealthcare

Follow us on Twitter @IBMHealthcare or www.twitter.com/ibmhealthcare

Join in the discussion on the Smarter Healthcare LinkedIn Group

Stock quotes in this article: IBM, NVS 

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,262.56 +89.32 0.55%
S&P 500 1,842.98 +12.37 0.68%
NASDAQ 4,034.1610 +11.4670 0.29%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs